Pharmacists play a vital role in specialty care, but intervention practices aren't standardized. This national survey of 24 health-system specialty pharmacies revealed wide variation in defining and documenting interventions, though most were pharmacist-led and recorded in EHRs. Standardizing these practices can improve care quality, highlight pharmacist impact, and strengthen patient outcomes.

By utilizing an automated, electronic alert in the EHR, pharmacists were notified of 65 patients that had a clinically meaningful SIBDQ score drop and were able to intervene and complete 81 pharmacist actions. Patients on a standard dose of specialty medication or who did not have a recent/in process specialty medication change were more likely to receive more than 1 pharmacist action.

This study described initial abemaciclib dose, dose modifications, and time to modification for patients initiating a dose of abemaciclib lower than the FDA-recommended starting dose of 150mg twice daily for HR+, HER2- early high-risk and metastatic breast cancer between 10/12/2021 and 8/31/2023. Dose modifications were common during the first 12 months, with 96% of patients with a dose modification having at least one dose increase and 47% having at least 1 dose decrease.

This national survey evaluated the scope and depth of didactic and experiential instruction on specialty pharmacy (SP) in schools/colleges of pharmacy in the United States. Results demonstrate th SP-related topics are sparsely covered in current didactic and experiential curriculum. SP topics and electives are more common in schools with SP-affiliated faculty. Many schools recognize the value and growth of SP and the importance of SP-related education to meet growing workforce needs.

This quality improvement project assessed implementation of a letter template to expedite appeal letter submission. Pre-implementation, 29% of appeals were submitted within 3 days of PA denial, 70% within 7 days, 88% within 14 days, and 100% within 35 days. Postimplementation 89% of appeals were submitted within 3 days, 97% within 7 days, and 100% within 14 days. Appeal approval rates were high at 93% in both the pre-implementation and postimplementation groups.

By utilizing an automated, electronic alert in the EHR, pharmacists were notified of 65 patients that had a clinically meaningful SIBDQ score drop and were able to intervene and complete 81 pharmacist actions. Patients on a standard dose of specialty medication or who did not have a recent/in process specialty medication change were more likely to receive more than 1 pharmacist action.